ZFIN ID: ZDB-FIG-190809-12
Lin et al., 2019 - Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers   11(6) Full text @ Cancers
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Anatomical Term:
Stage: Adult
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Adult

Fig. 5

Treatment with 419S1 and 420S1 blocked hepatocellular carcinoma (HCC) formation in Tg(fabp10a:HBx, p53) and Tg(fabp10a:src, p53) transgenic zebrafish. (AC) Dot-plot of the relative expression fold of cell-cycle-related genes ccne1cdk1, and cdk2 after drug treatment compared to control fish. DMSO-treated Tg(fabp10a:HBx, p53) and Tg(fabp10a:src, p53) transgenic fish exhibited high levels of ccne1cdk1, and cdk2 expression compared to control fish. DMSO- (black circle), 419S1- (red square), 420S1- (blue triangle), and Sorafenib (green diamond)-treated Tg(fabp10a:HBx, p53) and Tg(fabp10a:src, p53) transgenic fish demonstrated significantly decreased ccne1 expression compared to DMSO. (D,E) Percentage of fish with various histopathological features revealed by hematoxylin and eosin (H&E) staining after different drug treatments for one month. Red indicates HCC, orange denotes dysplasia, yellow represents hyperplasia, green denotes steatosis, and grey is normal hepatocyte. (F) Representative images of H&E stain (400 ×) after one month of 419S1, 420S1, or Sorafenib treatment. Top panels are Tg(fabp10a:HBx, p53) and bottom panels are Tg(fabp10a:src, p53) transgenic fish. Scare bar: 100 μm. *: 0.01 < p ≤ 0.05; **: 0.001 < p ≤ 0.01; ***: p ≤ 0.001.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
ccne1 tp53zdf1/zdf1; nn1002Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: sorafenib Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: sorafenib Adult liver RTPCR
cdk1 tp53zdf1/zdf1; nn1002Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: sorafenib Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: sorafenib Adult liver RTPCR
cdk2 tp53zdf1/zdf1; nn1002Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: sorafenib Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg control Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver RTPCR
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: sorafenib Adult liver RTPCR
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
tp53zdf1/zdf1; nn1002Tg control Adult liver ccne1 expression increased amount, abnormal
Adult liver cdk1 expression increased amount, abnormal
Adult liver cdk2 expression increased amount, abnormal
Adult liver dysplastic, abnormal
Adult liver hepatocellular carcinoma increased amount, abnormal
Adult liver hyperplastic, abnormal
Adult liver lipid increased amount, abnormal
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver ccne1 expression amount, ameliorated
Adult liver cdk1 expression amount, ameliorated
Adult liver cdk2 expression amount, ameliorated
Adult liver hepatocellular carcinoma amount, ameliorated
Adult liver lipid amount, ameliorated
Adult liver structure, ameliorated
tp53zdf1/zdf1; nn1002Tg chemical treatment by injection: sorafenib Adult liver ccne1 expression amount, ameliorated
Adult liver cdk1 expression amount, ameliorated
Adult liver cdk2 expression amount, ameliorated
Adult liver hepatocellular carcinoma amount, ameliorated
Adult liver lipid amount, ameliorated
Adult liver structure, ameliorated
tp53zdf1/zdf1; nn1004Tg control Adult liver ccne1 expression increased amount, abnormal
Adult liver cdk1 expression increased amount, abnormal
Adult liver cdk2 expression increased amount, abnormal
Adult liver dysplastic, abnormal
Adult liver hepatocellular carcinoma increased amount, abnormal
Adult liver hyperplastic, abnormal
Adult liver lipid increased amount, abnormal
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Adult liver ccne1 expression amount, ameliorated
Adult liver cdk1 expression amount, ameliorated
Adult liver cdk2 expression amount, ameliorated
Adult liver hepatocellular carcinoma amount, ameliorated
Adult liver lipid amount, ameliorated
Adult liver structure, ameliorated
tp53zdf1/zdf1; nn1004Tg chemical treatment by injection: sorafenib Adult liver ccne1 expression amount, ameliorated
Adult liver cdk1 expression amount, ameliorated
Adult liver cdk2 expression amount, ameliorated
Adult liver hepatocellular carcinoma amount, ameliorated
Adult liver lipid amount, ameliorated
Adult liver structure, ameliorated
Acknowledgments:
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancers